Sanofi and Blueprint Medicines Announce Collaboration
Ticker: SNYNF · Form: 6-K · Filed: Jun 2, 2025 · CIK: 1121404
| Field | Detail |
|---|---|
| Company | Sanofi (SNYNF) |
| Form Type | 6-K |
| Filed Date | Jun 2, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: collaboration, press-release, pharmaceutical
Related Tickers: BPMC
TL;DR
Sanofi is teaming up with Blueprint Medicines, filing details today.
AI Summary
On June 2, 2025, Sanofi announced a joint press release with Blueprint Medicines Corporation. This filing incorporates the press release as Exhibit 99.1, detailing their collaboration.
Why It Matters
This filing signals a potential strategic partnership or development agreement between two pharmaceutical companies, which could impact their respective product pipelines and market positions.
Risk Assessment
Risk Level: low — The filing is an informational report of a press release and does not contain new financial data or significant operational changes that would inherently increase risk.
Key Players & Entities
- Sanofi (company) — Registrant and collaborator
- Blueprint Medicines Corporation (company) — Collaborator
- June 2, 2025 (date) — Date of press release
FAQ
What is the primary purpose of this 6-K filing?
The primary purpose is to report a joint press release issued by Sanofi and Blueprint Medicines Corporation on June 2, 2025, as required by SEC regulations.
Which exhibit is incorporated by reference into this filing?
Exhibit 99.1, a joint press release issued by Sanofi and Blueprint Medicines Corporation on June 2, 2025, is incorporated by reference.
What is Sanofi's SEC file number?
Sanofi's SEC file number is 001-31368.
What is Sanofi's Standard Industrial Classification code?
Sanofi's Standard Industrial Classification code is 2834, for Pharmaceutical Preparations.
Where is Sanofi's principal executive office located?
Sanofi's principal executive office is located at 46, avenue de la Grande Armée, 75017 Paris, France.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 2, 2025 regarding Sanofi (SNYNF).